Abstract
Limosilactobacillus reuteri INIA P572 is a strain able to produce the antimicrobial compound reuterin in dairy products, exhibiting a protective effect against some food-borne pathogens. In this study, we investigated some probiotic properties of this strain such as resistance to gastrointestinal passage or to colonic conditions, reuterin production in a colonic environment, and immunomodulatory activity, using different in vitro and in vivo models. The results showed a high resistance of this strain to gastrointestinal conditions, as well as capacity to grow and produce reuterin in a human colonic model. Although the in vitro assays using the RAW 264.7 macrophage cell line did not demonstrate direct immunomodulatory properties, the in vivo assays using a Dextran Sulphate Sodium (DSS)-induced colitic mice model showed clear immunomodulatory and protective effects of this strain.
Highlights
Limosilactobacillus reuteri is a heterofermentative lactobacilli recognized as a normal inhabitant of the human and animal gut [1,2,3,4]
Serial dilutions of L. reuteri INIA P572 were plated in Rogosa agar, while serial dilutions of L. reuteri INIA P572:aFP were plated in Rogosa agar with
L. reuteri INIA P572 and L. reuteri INIA P572:aFP strains showed a high resistance to pH 3-simulated gastric conditions, with bacterial counts recovered only one log unit below than the initial level
Summary
Limosilactobacillus reuteri is a heterofermentative lactobacilli recognized as a normal inhabitant of the human and animal gut [1,2,3,4]. Some of the probiotic properties attributed to this species include the shortening of infant diarrheal events [9], the decrease in total and LDL-cholesterol levels in hypercholesterolemic subjects [10], the protection against Helicobacter pylori infection [11] or the reduction of intestinal inflammation in different experimental models of colitis in rodents [12,13,14,15,16,17] Some of these probiotic properties are related to the capacity of certain L. reuteri strains to produce the antimicrobial compound reuterin during the anaerobic bioconversion of glycerol [8,18,19]. Ingestion of 109 –1010 alive L. reuteri bacteria is considered well tolerated and safe, even in immunodeficient individuals [24,25]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
